Geron Corporation is a biotechnology company focused on developing innovative therapies for cancer treatment, particularly through its lead product candidate, which targets hematologic malignancies
The company is dedicated to advancing its proprietary telomerase technology to create effective and safe treatment options for patients with various types of cancer. By leveraging its scientific expertise and clinical research capabilities, Geron aims to address unmet medical needs and improve patient outcomes in the oncology field.
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Geron securities between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”). Investors have until May 12, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) securities during the period from June 7, 2024, through February 25, 2025 (“the Class Period”). Investors have until May 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 225,000 shares of its common stock, consisting of stock options to purchase an aggregate of 150,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 75,000 shares of common stock, to three newly hired employees as an inducement material to their acceptance of employment with the Company.
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), have until May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit. Captioned Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal.), the Geron class action lawsuit charges Geron as well as certain of Geron’s top current and former executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Potvin v. Geron Corporation, No. 25-cv-02563 (N.D. Cal.).
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) and certain of its officers.
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Geron Corporation (NASDAQ: GERN) securities between June 7, 2024 to February 25, 2025. Geron is a commercial-stage biopharmaceutical company with a focus on blood cancer. Geron’s primary product is a telomerase inhibitor, imetelstat, which the Company sells under the brand name, Rytelo.
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), have until May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit. Captioned Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal.), the Geron class action lawsuit charges Geron and certain of Geron’s top current and former executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Potvin v. Geron Corporation, No. 25-cv-02563 (N.D. Cal.).
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their Options
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Geron Corporation (NASDAQ: GERN) securities between June 7, 2024 and February 25, 2025, both dates inclusive (the “Class Period”). Geron is a commercial-stage biopharmaceutical company.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has granted marketing authorization for RYTELO® (imetelstat) as a monotherapy for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (ESAs). Lower-risk MDS is a progressive blood cancer with high unmet need, where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and decreased quality of life.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John “Chip” A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O’Farrell has been appointed as Chair of the Board.
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) on behalf of Geron stockholders. Our investigation concerns whether Geron has violated the federal securities laws and/or engaged in other unlawful business practices.
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in fireside chats at the following investor conferences:
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 180,000 shares of its common stock, consisting of stock options to purchase an aggregate of 120,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 60,000 shares of common stock, to two newly hired employees as an inducement material to their acceptance of employment with the Company.
